Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Condition(s):Head and Neck Cancer; Metastatic Cancer; OligoprogressiveLast Updated:December 12, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Head and Neck Cancer; Metastatic Cancer; OligoprogressiveLast Updated:December 12, 2023Recruiting
Condition(s):Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung CancerLast Updated:August 4, 2022Terminated
Condition(s):Malignant Prostate NeoplasmLast Updated:January 19, 2024Recruiting
Condition(s):Glottic CarcinomaLast Updated:February 21, 2024Active, not recruiting
Condition(s):Oligometastatic Disease; Oligoprogression; Toxicity Due to Radiotherapy; Quality of LifeLast Updated:January 23, 2024Not yet recruiting
Condition(s):Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung CarcinomaLast Updated:September 21, 2023Completed
Condition(s):Colorectal CancerLast Updated:March 15, 2024Not yet recruiting
Condition(s):Recurrent Epithelial Ovarian CancerLast Updated:November 24, 2023Recruiting
Condition(s):Liver Neoplasms; Hepatocellular CancerLast Updated:November 7, 2017Terminated
Condition(s):Non-Small Cell Lung CancerLast Updated:February 29, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.